Study of CEP-701 in Treatment of Prostate Cancer
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
Prostate Cancer
DRUG: CEP-701
A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.